|
ES2740424T3
(es)
|
2009-03-13 |
2020-02-05 |
Agios Pharmaceuticals Inc |
Métodos y composiciones para trastornos relacionados con la proliferación celular
|
|
CA2758071C
(en)
|
2009-04-06 |
2018-01-09 |
Agios Pharmaceuticals, Inc. |
Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
|
|
EP2448581B1
(en)
|
2009-06-29 |
2016-12-07 |
Agios Pharmaceuticals, Inc. |
Therapeutic compositions and related methods of use
|
|
SG10201403696UA
(en)
|
2009-06-29 |
2014-10-30 |
Agios Pharmaceuticals Inc |
Therapeutic compounds and compositions
|
|
EP3064595B1
(en)
|
2009-10-21 |
2019-02-27 |
Agios Pharmaceuticals, Inc. |
Methods for cell-proliferation-related disorders
|
|
EP2525790B1
(en)
|
2009-10-21 |
2020-05-27 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
|
CA2821975A1
(en)
|
2010-12-17 |
2012-06-21 |
Shunqi Yan |
N-(4-(azetidine-1-carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 pkm2 modulators
|
|
WO2012088314A1
(en)
|
2010-12-21 |
2012-06-28 |
Agios Pharmaceuticals, Inc. |
Bicyclic pkm2 activators
|
|
TWI549947B
(zh)
|
2010-12-29 |
2016-09-21 |
阿吉歐斯製藥公司 |
治療化合物及組成物
|
|
JP6272754B2
(ja)
|
2011-05-03 |
2018-01-31 |
アジオス ファーマシューティカルズ， インコーポレイテッド |
ピルビン酸キナーゼ活性化剤の使用方法
|
|
CN102827170A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
AU2012313888B2
(en)
*
|
2011-09-27 |
2016-03-31 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
|
|
LT2800743T
(lt)
|
2012-01-06 |
2018-06-25 |
Agios Pharmaceuticals, Inc. |
Terapiškai aktyvūs junginiai ir jų panaudojimo būdai
|
|
US9474779B2
(en)
*
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
NZ706999A
(en)
|
2012-10-15 |
2018-12-21 |
Agios Pharmaceuticals Inc |
Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
KR20150131224A
(ko)
|
2013-03-14 |
2015-11-24 |
노파르티스 아게 |
돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
|
WO2014197835A2
(en)
|
2013-06-06 |
2014-12-11 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
|
ES2807582T3
(es)
|
2013-07-11 |
2021-02-23 |
Agios Pharmaceuticals Inc |
Compuestos N,6-bis(aril o heteroaril)-1,3,5-triazina-2,4-diamina como inhibidores de mutantes IDH2 para el tratamiento del cáncer
|
|
US10376510B2
(en)
|
2013-07-11 |
2019-08-13 |
Agios Pharmaceuticals, Inc. |
2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
|
|
WO2015003355A2
(en)
*
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
WO2015010297A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
ES2654051T3
(es)
|
2013-12-05 |
2018-02-12 |
Pfizer Inc. |
Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
|
|
BR112016018604A2
(pt)
|
2014-02-11 |
2017-08-08 |
Bayer Pharma AG |
Benzimidazol-2-aminas como inibidores de midh1
|
|
CA2939021C
(en)
|
2014-02-11 |
2022-07-12 |
Bayer Pharma Aktiengesellschaft |
Benzimidazol-2-amines as midh1 inhibitors
|
|
US9968595B2
(en)
|
2014-03-14 |
2018-05-15 |
Agios Pharmaceuticals, Inc. |
Pharmaceutical compositions of therapeutically active compounds
|
|
US9926286B2
(en)
*
|
2014-05-09 |
2018-03-27 |
Shanghai Syncores Technologies Inc. Ltd. |
Vortioxetine intermediate and synthesis process thereof
|
|
MX372964B
(es)
|
2014-09-19 |
2020-03-27 |
Forma Therapeutics Inc |
Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
|
|
KR102209667B1
(ko)
|
2014-09-19 |
2021-01-29 |
포르마 세라퓨틱스 인크. |
돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체
|
|
AU2015317321B2
(en)
|
2014-09-19 |
2020-03-12 |
Forma Therapeutics, Inc. |
Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
|
|
EP3201185B1
(en)
*
|
2014-09-19 |
2018-11-21 |
Forma Therapeutics, Inc. |
Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
|
|
CN107428690B
(zh)
|
2014-12-22 |
2021-04-13 |
美国政府健康及人类服务部 |
可用于治疗癌症的突变idh1抑制剂
|
|
WO2016171755A1
(en)
*
|
2015-04-21 |
2016-10-27 |
Forma Therapeutics, Inc. |
Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
|
|
US9624216B2
(en)
|
2015-04-21 |
2017-04-18 |
Forma Therapeutics, Inc. |
Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
|
|
RS64777B1
(sr)
|
2015-06-11 |
2023-11-30 |
Agios Pharmaceuticals Inc |
Postupci upotrebe aktivatora piruvat kinaze
|
|
WO2017035057A1
(en)
*
|
2015-08-24 |
2017-03-02 |
The Methodist Hospital |
Compositions and methods for treating ewing family tumors
|
|
DK3362066T3
(da)
|
2015-10-15 |
2021-11-22 |
Les Laboratoires Servier Sas |
Kombinationsterapi til behandling af maligniteter
|
|
UA123401C2
(uk)
|
2015-10-15 |
2021-03-31 |
Аджиос Фармасьютікалз, Інк. |
Комбінована терапія для лікування злоякісних пухлин
|
|
JP6961879B2
(ja)
*
|
2015-12-30 |
2021-11-05 |
レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ |
変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
|
|
WO2017153952A1
(en)
*
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
CN109071429B
(zh)
*
|
2016-03-22 |
2021-04-02 |
正大天晴药业集团股份有限公司 |
丙啶磺酰胺类化合物及其使用方法
|
|
US20180369206A1
(en)
|
2017-04-24 |
2018-12-27 |
Aurigene Discovery Technologies Limited |
Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
|
|
IL270066B2
(en)
|
2017-04-24 |
2023-10-01 |
Aurigene Oncology Ltd |
Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
|
|
CN109897044A
(zh)
*
|
2017-12-07 |
2019-06-18 |
北京大学 |
抗神经病理性疼痛化合物及其制备方法
|
|
KR102861339B1
(ko)
|
2018-02-20 |
2025-09-19 |
르 라보레또레 쎄르비에르 |
삼치환 벤조트리아졸 유도체의 사용 방법
|
|
US11497743B2
(en)
|
2018-05-16 |
2022-11-15 |
Forma Therapeutics, Inc. |
Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
|
|
US11738018B2
(en)
|
2018-05-16 |
2023-08-29 |
FORMA Therapeuetics, Inc. |
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
|
|
US11311527B2
(en)
|
2018-05-16 |
2022-04-26 |
Forma Therapeutics, Inc. |
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
|
|
US11013734B2
(en)
|
2018-05-16 |
2021-05-25 |
Forma Therapeutics, Inc. |
Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
|
|
WO2019222551A1
(en)
|
2018-05-16 |
2019-11-21 |
Forma Therapeutics, Inc. |
Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
|
|
US11013733B2
(en)
|
2018-05-16 |
2021-05-25 |
Forma Therapeutics, Inc. |
Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
|
|
US20210196701A1
(en)
|
2018-05-16 |
2021-07-01 |
Forma Therapeutics, Inc. |
Inhibiting mutant idh-1
|
|
CN108822082B
(zh)
*
|
2018-06-06 |
2020-11-03 |
青岛科技大学 |
一种含氟吡啶哌嗪酰胺类化合物及其应用
|
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
|
CN116768806B
(zh)
*
|
2022-03-11 |
2026-01-02 |
中国农业大学 |
取代的1,2,3-三唑类化合物及其制备方法和在防治植物病害中的用途
|
|
CN114685399A
(zh)
*
|
2022-04-26 |
2022-07-01 |
河北广祥制药有限公司 |
一种乌拉地尔中间体1-(2-甲氧基苯基)哌嗪及其盐的制备方法
|
|
CN116425653A
(zh)
*
|
2023-03-22 |
2023-07-14 |
烟台盛凯伦化学科技有限公司 |
一种n,n’-二(对乙氧基苯基)-1,4-苯二甲亚胺的制备方法
|
|
AU2024271540A1
(en)
*
|
2023-05-18 |
2025-11-27 |
Concarlo Therapeutics, Inc. |
Small molecule inhibitors of p27
|
|
WO2026088050A1
(en)
*
|
2024-10-23 |
2026-04-30 |
Fondazione Per L'istituto Oncologico Di Ricerca (Ior) |
Small molecule inhibitor of foxa1 and foxa2 for the treatment of foxa1/foxa2-dependent cancers or other diseases
|